ARTICLE | Finance
With second asset nearing clinic, Escient to test new mast cell targets with $120M series C
Newly backed by NEA, Abingworth and Forge, the biotech is advancing a MRGPRX2 program for urticaria behind its clinical asset for pruritus
December 1, 2022 10:19 PM UTC
With a first-in-human Phase I trial soon to begin and another Phase II study already started, Escient is aiming to deploy its new $120 million series C round to show clinical proof of concept in innovative areas of mast cell biology and dermatology.
New Enterprise Associates, Abingworth and Forge Life Science Partners led the round, which gives Escient Pharmaceuticals Inc. runway to advance its lead programs, an MRGPRX2 inhibitor to treat chronic urticaria and atopic dermatitis and an MRGPRX4 inhibitor for pruritus associated with liver or kidney disease...